ESTRO shared on X/Twitter:
“Results from the TRAP trial presented at ESTRO24: this phase-II trial explores the addition of SBRT to androgen receptor pathway inhibitor treatment in patients with oligoprogressive castrate-resistant prostate cancer.”
Source: ESTRO/X